Blood Clot

Blood Clot risk for Post-COVID Lasts at Least 6 Months

Researchers said that Covid-19 disease increases people’s risk of developing a dangerous blood clot and bleeding for months after infection.

Blood Clot risk for Post-COVID

The new findings recommend that COVID-19 is an independent risk factor or issue for

  • Deep venous thrombosis,
  • Pulmonary embolism and
  • Bleeding.

“Our findings arguably support [treatment] to avoid thrombotic events, especially for high-risk patients, and strengthen the importance of vaccination against COVID-19,” the study authors concluded in a report published April 6 in the British Medical Journal.

Blood Clot

In a journal news release, the researchers noted that while the additional risk of clots and bleeding was known, it was not clear how long it lasted.

To find out, investigators compared more than 1 million people in Sweden who tested positive for COVID-19 between February 1, 2020 and May 25, 2021, with a control group of more than 4 million people who did not test positive. COVID test.

Compared to the control group, COVID-19 patients had a higher risk of developing deep vein thrombosis, or DVT, (a blood clot in the leg) for up to three months after infection; pulmonary embolism (a blood clot in the lung) for up to six months; Bleeding occurred for up to two months.

After accounting for a number of potentially important factors, the researchers concluded that people with COVID-19 have a five times higher risk of developing DVT. The risk of developing a pulmonary embolism is 33 times greater; The risk of bleeding nearly doubled at 30 days after injury.

DVT occurred in 0.04% of COVID-19 patients and 0.01% of control patients. Pulmonary embolism occurred in 0.17% of COVID-19 patients and 0.004% of control patients. Bleeding occurred in 0.10% of COVID-19 patients and 0.04% of control patients, according to the report.

Blood Clot

The risks of thrombosis and bleeding were higher in patients who had more severe COVID-19, those with other health conditions and those infected during the first wave rather than in the second and third waves. This could be explained by improved treatment and vaccine coverage in older patients after the first wave, the researchers said.

The study found that even patients with mild COVID-19 were more likely to develop DVT and pulmonary embolism. While no increased risk of bleeding was found in those with mild COVID virus, there was a significant increase in patients with more severe infections.

The study was led by Anne Marie Force Connolly of the Department of Clinical Microbiology at Umeå University in Sweden.

Frederick Hu of the University of Glasgow’s Institute of Health and Welfare in Scotland and colleagues wrote an editorial accompanying the findings.

Although many countries have removed pandemic restrictions and shifted their focus to coexisting with COVID-19, this study “reminds us of the need to be vigilant about complications associated with even mild SARS-CoV-2 infection, including blood clots,” the team He wrote.

More information

There’s more on COVID-19 and the blood at the U.S. National Heart, Lung, and Blood Institute.

SOURCE: BMJ, news release, April 6, 2022